Medical management of Paget's disease of bone: Indications for treatment and review of current therapies

Journal of Bone and Mineral Research

Volumn 21, Issue SUPPL. 2, 2006, Pages

  Siris, Ethel S ^a   Lyles, Kenneth W ^b   Singer, Frederick R ^c   Meunier, Pierce J ^d  

^a Howard Hughes Medical Institute   (United States)

^b DUKE UNIVERSITY   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

bisphosphonates; indications for treatment; medical management; Paget's disease

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

DRUG EFFECT; HUMAN; OSTEOCLAST; PAGET BONE DISEASE; REVIEW;

DIPHOSPHONATES; HUMANS; OSTEITIS DEFORMANS; OSTEOCLASTS;

EID: 34047234560     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1359/jbmr.06s218     Document Type: Conference Paper

References (24)

1. Lyles KW, Siris ES, Singer FR, Meunier PJ, 2001 A clinical approach to the diagnosis and management of Paget's disease of bone. J Bone Miner Res 16: 1379-1387. (Pubitemid 32675190)
2. Delmas PD, Meunier PJ, 1997 The management of Paget's disease of bone. N Engl J Med 336: 558-566. (Pubitemid 27085738)
3. Siris ES, Feldman F, 1997 Natural history of untreated Paget's disease of the tibia. J Bone Miner Res 12: 691-692. (Pubitemid 27155230)
4. Meunier PJ, Vignot E, 1995 Therapeutic strategy in Paget's disease of bone. Bone 17: 489S-491S.
5. Bickerstaff DR, Douglas DL, Burke PH, O'Doherty DP, Kanis JA, 1990 Improvement in facial deformity of Paget's disease treated with diphosphonates. J Bone Joint Surg Br 72: 132-136. (Pubitemid 20035834)
6. Murdin L, Yeoh LH, 2005 Hearing loss treated with pamidronate. J R Soc Med 98: 272-274. (Pubitemid 40966319)
7. Canfield RE, Rosner W, Skinner J, McWhorter J, Resnick L, Feldman F, Kammerman S, Ryan K, Kunigonis M, Bohne W, 1977 Diphosphonate therapy of Paget's disease of bone. J Clin Endocrinol Metab 44: 96-106. (Pubitemid 8030788)
8. McClung MR, Tou CPK, Goldstein NH, Picot C, 1995 Tiludronate therapy for Paget's disease of bone. Bone 17: 493S-496S.
9. Roux C, Gennari C, Farrerons J, Devogelaer JP, Mulder H, Kruse HP, Picot C, Titeux L, Reginster JY, Dougados M, 1995 Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 38: 851-885.
10. Siris ES, Jacobs TP, Canfield RE, 1980 Paget's disease of bone. Bull N Y Acad Med 56: 285-304. (Pubitemid 10078826)
11. Siris ES, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy WA, Reda C, Rude R, Seton M, Tiegs R, Thompson D, Tucci JR, Yates AJ, Zimering M, 1996 Comparative study of alendronate vs. etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81: 961-967. (Pubitemid 26083954)
12. Reid I, Nicholson GC, Weinstein RS, Hosking DJ, Cundy T, Kotowicz MA, Murphy WA Jr, Yeap S, Dufresne S, Lombardi A, Musliner TA, Thompson DE, Yates AJ, 1996 Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized placebo-controlled trial. Am J Med 101: 341-348. (Pubitemid 26392850)
13. Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ, 1999 A prospective, multicenter, randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 106: 513-520. (Pubitemid 29231101)
14. Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL, 1987 Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). BMJ 295: 1301-1305. (Pubitemid 18003542)
15. Siris ES, 1994 Perspectives: A practical guide to the use of pamidronate in the treatment of Paget's disease. J Bone Miner Res 9: 303-304. (Pubitemid 24080565)
16. Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ, 1999 Effects of multiple intravenous pamidronate courses in Paget's disease of bone. Rev Rhum Engl Ed 66: 467-476. (Pubitemid 29500793)
17. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL, 2004 Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62: 527-534. (Pubitemid 38542516)
18. Carter G, Goss AN, Doecke C, 2005 Bisphosphonates and avascular necrosis of the jaw: A possible association. Med J Aust 182: 413-415. (Pubitemid 40561698)
19. Reid IR, Miller P, Lyles K, Fraser W, Brown J, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D, 2005 A single infusion of zoledronic acid improves remission rates in Paget's disease: A randomized controlled comparison with risedronate. N Engl J Med 353: 898-908. (Pubitemid 41247929)
20. DeRose J, Singer F, Avramides A, Flores A, Dziadiw R, Baker RK, Wallach S, 1974 Response of Paget's disease to porcine and salmon calcitonins: Effects of long term treatment. Am J Med 56: 858-866.
21. Singer FR, Ginger K, 1991 Resistance to calcitonin. In:, Singer FR, Wallach S, eds. Paget's Disease of Bone: Clinical Assessment, Present and Future therapy. Elsevier, New York, NY, USA, 75-85.
22. Siris ES, 1998 Clinical Review: Paget's disease of bone. J Bone Miner Res 13: 1061-1065. (Pubitemid 28311773)
23. Altman RD, 1985 Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone. Am J Med 79: 583-590. (Pubitemid 16191211)
24. Gutteridge DH, Ward LC, Stewart GO, Retallack RW, Will RK, Prince RL, Criddle A, Bhagat CI, Stuckey BG, Price RI, Kent GN, Faulkner DL, Geelhoed E, Gan SK, Vasikaran S, 1999 Paget's disease: Acquired resistance to one aminobisphosphonate with retained response to another. J Bone Miner Res 14: S2; 79-84. (Pubitemid 29455804)